Related Experiment Videos
The strengths and limitations of E/e' in heart failure with preserved ejection fraction
Masaru Obokata1, Barry A Borlaug1
1Department of Cardiovascular Medicine, Mayo Clinic Rochester, MN, USA.
European Journal of Heart Failure
|June 23, 2018
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Association between locomotor muscle quality and cardiac function during exercise in heart failure with preserved ejection fraction.
European journal of heart failure·2024
Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy.
Journal of the American College of Cardiology·2024
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
The New England journal of medicine·2024
Prevalence of HFpEF in Isolated Severe Secondary Tricuspid Regurgitation.
JAMA cardiology·2024
Clinical trajectory and disease progression in patients with cardio-renal-metabolic syndrome: the CaReMap observational study.
European journal of heart failure·2026
GDMT is Associated with Reduced Loop Diuretic Requirements, Whereas Diuretic Dose Does Not Modify GDMT Benefit in Heart Failure: STRONG-HF.
European journal of heart failure·2026
Kidney function decline, heart failure hospitalization, and the effect of empagliflozin in heart failure: an EMPEROR-pooled analysis.
European journal of heart failure·2026
Pharmacological treatment strategies to prevent heart failure across the cardiovascular-kidney-metabolic spectrum: an EJHF Expert Consensus Statement.
European journal of heart failure·2026
Effectiveness of Finerenone in Slowing Chronic Kidney Disease Progression After Hospitalization for Heart Failure: A FIDELITY Subgroup Analysis.
European journal of heart failure·2026